-
Announcement of the State Food and Drug Administration on the conversion of compound Banlangen Granules into over-the-counter drugs (No. 58 of 2021)
Time of Update: 2021-11-14
The list of varieties (Annex 1) and the template of non-prescription drug instructions (Annex 2) are released together .
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
-
The National Medical Insurance Bureau issued the national procurement renewal document: no "only bargaining, no quantity"!
Time of Update: 2021-11-14
In addition, in response to previous penalties for winning bids for failing to supply the agreed procurement volume in accordance with the agreement, the "Notice" also made provisions on "strengthening credit and performance evaluation", "improving supporting policies", and "strengthening performance supervision".
-
ADC drugs enter the hot spot of industry attention, and domestic research and development is booming
Time of Update: 2021-11-14
7 billion yuan, invest in the construction of the company’s Hangzhou biopharmaceutical project, engage in the research and development of anti-tumor ADC drugs, and set up other Subsidiaries and other industries .
-
TOP10 failed clinical studies in October 2021
Time of Update: 2021-11-14
Phase III study of Canakinumab in the treatment of non-small cell lung cancerNovartis announced on October 25 that the IL-1β inhibitor Canakinumab (canakinumab, ACZ885) combined with pembrolizumab plus platinum dual-drug chemotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) The phase III clinical study (CANOPY-1) failed to achieve the primary endpoints of improving overall survival (OS) and progression-free survival (PFS) .
-
Novartis' potential "first-in-class" complement inhibitor reaches phase 2 clinical endpoint
Time of Update: 2021-11-14
Today, Novartis announced that its potential "first-in-class" oral factor B inhibitor iptacopan (LNP023) has reached its primary clinical endpoint in a phase 2 clinical trial for the treatment of patients with C3 glomerulopathy (C3G).
-
Johnson & Johnson, U.S., etc. are all developing the first FcRn-targeted new drug. When will it arrive?
Time of Update: 2021-11-14
In addition, another important research direction in this field is to develop drugs to inhibit the binding of endogenous FcRn and IgG, thereby treating autoimmune diseases driven by autoantibody .
-
The place will carry out the purchase of low-value consumables with a quantity, and the product decline may be very substantial
Time of Update: 2021-11-14
The notice pointed out that after the implementation of the Internet, in addition to first aid and other clinical needs, low-value medical consumables and test reagents used by public medical and health institutions in the city must be purchased on the procurement platform.
-
Asia Pacific Pharmaceuticals Mosapride Citrate Granules Obtained Drug Registration Certificate
Time of Update: 2021-11-14
On November 4, Asia-Pacific Pharmaceuticals issued an announcement stating that the company had received the "Drug Registration Certificate" for the chemical mosapride citrate granules approved and issued by the National Medical Products Administration .
No other company has obtained the registration certificate of the drug granules.
-
The peptide drug market in my country has further expanded, and these companies are worth recommending
Time of Update: 2021-11-14
As a domestic peptide drug company, Sino Bio has always established its brand with innovative peptide drug pharmaceutical research services and peptide product customized production services, based on the large-scale production and sales of raw materials .
-
Announcement of the State Food and Drug Administration on the conversion of aloe pearl capsule prescription drugs to over-the-counter drugs (No. 115 of 2021)
Time of Update: 2021-11-14
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
Variety of non-prescription drug instructions template State Drug Administration September 23, 2021 State Drug Administration Announcement No.
-
Yangtze River hits 1 billion injections!
Time of Update: 2021-11-14
Since the beginning of this year, Yangtze River has received 19 injections, covering multiple therapeutic areas such as anti-tumor drugs, anesthetics, and contrast agents .
0 Chinese Drug Evaluation DatabaseSince the beginning of this year, Yangtze River has received 19 injections, covering multiple subcategories such as anti-tumor drugs, anesthetics, and contrast agents.
-
National Medical Insurance Administration: In principle, all national drug procurement agreements should continue to carry out centralized procurement after the expiration of the agreement
Time of Update: 2021-11-14
44 The medical insurance bureaus of all provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps: In order to implement the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Drug Centralized and Volume Procurement" (Guobanfa [2021] No.
-
Announcement of the State Food and Drug Administration on the Implementation of the Application of Electronic General Technical Documents for Drugs (No. 119 of 2021)
Time of Update: 2021-11-14
The Drug Evaluation Center of the National Medical Products Administration will do a good job in the relevant technical guidance during the implementation of this announcement .
-
Announcement of the State Food and Drug Administration on the publication of the list of medical pharmacy professional publications that allow the publication of prescription drug advertisements (No. 64 of 2021)
Time of Update: 2021-11-14
According to the "Advertising Law of the People's Republic of China", the National Health Commission of the People's Republic of China agreed to include the "Journal of Alzheimer's Disease and Relate
-
In order to ensure drug supply and stable prices, relevant departments in my country are strengthening the security measures for listed drugs
Time of Update: 2021-11-14
Since 2021, the leading department of the consultation and linkage mechanism for the supply and guarantee of shortage of medicines at the national and provincial levels has worked with relevant units to focus on the implementation of the national shortage of medicines list and the key monitoring list of clinically necessary and easy-to-shortage medicines, and continue to promote the sharing of medicine-related information.
-
Yuandong Bio-Repaglinide Metformin Tablets Obtained "Drug Registration Certificate"
Time of Update: 2021-11-14
Repaglinide and metformin tablets are compound preparations, the components of which are repaglinide and metformin hydrochloride .
It is suitable for patients who have been treated with glinide and metformin hydrochloride in combination, or treated with glinide or metformin hydrochloride monotherapy.
-
Announcement of the State Food and Drug Administration on the conversion of four drugs including Shenqi Wuweizi Capsules into over-the-counter drugs (No. 100 of 2021)
Time of Update: 2021-11-14
The list of varieties (Annex 1) and the template of non-prescription drug instructions (Annex 2) are released together .
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
-
Cumulative savings of about 250 billion yuan!
Time of Update: 2021-11-14
The implementation of centralized procurement has significantly reduced the prices of commonly used drugs for the treatment of common diseases such as high blood pressure, diabetes, hyperlipidemia, cancer, and mental diseases, with an average drop of more than 50%.
-
Announcement of the State Food and Drug Administration on the conversion of Liubo Zhangmin liniment prescription drugs into non-prescription drugs (No. 93 of 2021)
Time of Update: 2021-11-14
Variety non-prescription drug instruction sheet template (82 ml) State Food and Drug Administration July 9, 2021 State Drug Administration Announcement No.
-
Check the current status of clinical trials of domestic children's anti-tumor drugs!
Time of Update: 2021-11-14
Drug clinical trial registration and information disclosure platform [1]As of November 1, 2021, search with "children", a total of 616 clinical trials were retrieved, 6 of which were indicated as "tumor", and only 2 were related to new anti-tumor drugs (entratinib, larotrectinib) ) .